Literature DB >> 1792190

Somatotropic adenomas without acromegaly.

J Trouillas1, G Sassolas, B Loras, B Velkeniers, M Raccurt, L Chotard, F Berthezène, J Tourniaire, C Girod.   

Abstract

Seventeen somatotropic adenomas removed from patients without acromegaly were studied. Thirteen of them presented as a prolactinoma with amenorrhea and/or galactorrhea and elevated serum PRL levels. According to basal serum GH levels, the patients were divided into two groups, namely Group I: GH slightly elevated (n = 4) and group II: GH less than or equal to 5 micrograms/l (n = 13). The tumoral GH secretion was proved by immunocytochemistry in all cases and by intratumoral RIA, in vitro study and/or in situ hybridization in five of them. Pathological, clinical and biochemical relationships suggested two anatomoclinical aspects. In group I, the tumors were small, well-differentiated somatotropic adenomas with clinically silent GH hypersecretion. It is probably an early stage of the disease. In group II, the tumors were large with normal GH serum levels. They were poorly differentiated and secreted very low amounts of GH. In nine of them, PRL and/or PRL mRNA expression were also detected. These tumors do not secrete enough GH to increase serum levels and cause acromegaly. The somatotropic adenomas without acromegaly correspond to two anatomoclinical aspects of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1792190     DOI: 10.1016/s0344-0338(11)81065-4

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 2.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

3.  Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity.

Authors:  Akiko Yoneda; Toshiaki Sano; Shozo Yamada; Abdulkader Obari; Zhi Rong Qian; Elaine Lu Wang; Naoko Inosita; Eiji Kudo
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

4.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

5.  Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas.

Authors:  Ikuo Kobayashi; Hidehiro Oka; Heiji Naritaka; Yuichi Sato; Kiyotaka Fujii; Toru Kameya
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 6.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Absence of immunostaining for growth hormone in a subset of patients with acromegaly.

Authors:  Jason L Schroeder; Alejandro M Spiotta; Maria Fleseriu; Richard A Prayson; Amir H Hamrahian; Robert J Weil
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

8.  Molecular Pathology of the Pituitary Adenomas.

Authors:  Naoko Sanno; Robert Y. Osamura
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

9.  SUBCLINICAL ACROMEGALY DUE TO A PITUITARY CYSTIC SOMATOTROPH ADENOMA.

Authors:  Natalie Mora; Thanh D Hoang; Vinh Q Mai; Mohamed K M Shakir
Journal:  AACE Clin Case Rep       Date:  2019-01-30

10.  The silent variants of pituitary tumors: demographic, radiological and molecular characteristics.

Authors:  M E Torregrosa-Quesada; A García-Martínez; A Sánchez-Barbie; S Silva-Ortega; R Cámara; C Fajardo; C Lamas; I Aranda; A Pico
Journal:  J Endocrinol Invest       Date:  2021-01-21       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.